Does Wegovy Show Up on a Drug Test? Employer Guide

Quick answer: No. Wegovy (semaglutide) is not detected by standard urine drug tests, including 5-panel, 10-panel and DOT 49 CFR Part 40 panels, because none of them target it. A semaglutide-specific lab method exists, but it is not part of routine workplace screening, and Wegovy is not a controlled substance.

• Standard immunoassay cups and dip cards screen for specific drug classes, and semaglutide is not one of them.
• A result you cannot explain should go to lab confirmation (GC-MS or LC-MS/MS) and Medical Review Officer review, not be treated as a violation.
• Your policy should address prescription medications generally, not single out one brand.

What Wegovy Is and Why It Matters for Testing Programs

Wegovy is a brand-name injectable prescription of semaglutide, a GLP-1 receptor agonist used for chronic weight management. It is a peptide drug. It is not an opioid, stimulant, cannabinoid, benzodiazepine or other substance of abuse, and it is not a scheduled controlled substance. Because use has grown quickly, clinics, staffing firms and probation offices increasingly get asked whether it affects a screen.

What a Standard Panel Actually Detects

Workplace urine screens use immunoassay technology, in which antibodies bind to a particular drug or metabolite at or above a set cutoff concentration. The federal 5-panel under the SAMHSA/HHS workplace program, which DOT adopts in 49 CFR Part 40, covers marijuana metabolite, cocaine metabolite, opiates, amphetamines and phencyclidine (PCP). The DOT initial test cutoffs in 49 CFR 40.87 are:

• Marijuana metabolites (THCA): 50 ng/mL
• Cocaine metabolite (benzoylecgonine): 150 ng/mL
• Codeine/morphine: 2,000 ng/mL
• Hydrocodone/hydromorphone/oxycodone/oxymorphone: 300 ng/mL
• Amphetamine/methamphetamine: 500 ng/mL
• PCP: 25 ng/mL

Semaglutide has a completely different structure from these targets, and no panel's antibodies are built to find it. Non-regulated 10-panel cups add classes such as benzodiazepines, barbiturates, methadone and others, but not GLP-1 drugs.

Can semaglutide ever be detected?

Yes, but only through a purpose-built analytical method, typically liquid chromatography with tandem mass spectrometry (LC-MS/MS) set up in a laboratory for that analyte. That is a clinical or research request, not a routine employment or court screen. If your program has no reason to look for it, it will not be looked for.

Comparison: Common Test Types and Wegovy

What This Means for a Buyer

If you supply collection sites or run a testing program, you do not need a special product for Wegovy. A standard device cleared and labeled for the panel you need is the right choice. Review the drug test cups for on-site multi-panel screening, or drug test dip cards for a lower-cost format. Check each device's FDA clearance and CLIA-waiver status in the manufacturer's package insert for your intended use, and read results within the time window stated in the insert.

Reading results correctly

1. Check the temperature strip and validity indicators as soon as the sample is collected.
2. Read the result inside the window in the package insert, and do not read after it.
3. Treat any line, even faint, in the test region as negative for that drug, per the insert.
4. Treat a missing test line as a non-negative (presumptive positive) result.
5. Send non-negative samples for laboratory confirmation before any action.

Policy Checklist for Employers, Clinics and Courts

• Define the panel in writing, and confirm that it lists drug classes, not brand names.
• State that lawfully prescribed medications are reviewed through a medical review process.
• Require lab confirmation of every non-negative screen before adverse action.
• Do not ask donors about medical conditions at the collection site beyond what your procedure requires.
• For DOT-regulated employees, follow 49 CFR Part 40 and use a certified MRO.
• Keep chain-of-custody forms and lot numbers for every device used.
• Have counsel review any policy touching medical information or accommodation.
• Pair testing with employment background checks where your hiring process calls for both.

Why Wegovy Users Should Not Worry About a False Positive

Immunoassays can cross-react with unrelated molecules, which is why confirmation exists. But Wegovy is not known as a common cross-reactant on standard panels. If an unexpected non-negative does occur, confirmation by mass spectrometry separates true drug presence from interference, and the MRO can review any medication disclosed by the donor.

Need Help Choosing a Panel?

ASC supplies wholesale urine cups, dip cards, oral fluid tests, breathalyzers, DOT-compliant collection kits and lab confirmation to clinics, hospitals, treatment centers, courts, labs and employers. Contact our team to match a panel to your program.

FAQ

Does Wegovy show up on a standard 10-panel drug test?

No. A 10-panel screens specific drug classes, and semaglutide is not among them, so Wegovy use does not produce a positive.

Does Wegovy show up on a DOT drug test?

No. The DOT panel under 49 CFR Part 40 tests for marijuana, cocaine, opioids, amphetamines and PCP only, and semaglutide is not on it.

Could Wegovy cause a false positive?

It is not known as a common cross-reactant on standard immunoassays. Any non-negative result should be confirmed by a laboratory and reviewed by an MRO before action.

Should our policy mention Wegovy?

Usually no. Write the policy around drug classes and a medical review process for lawful prescriptions, and have counsel review it.

Sources

• SAMHSA: Workplace Drug Testing
• U.S. DOT: 49 CFR Part 40 Overview
• eCFR: 49 CFR 40.87 Initial Test Cutoff Concentrations

This article is general information, not legal or medical advice.